Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 566

1.

Quality of Care in Inflammatory Bowel Disease: Actual Health Service Experiences Fall Short of the Standards.

Mikocka-Walus A, Massuger W, Knowles SR, Moore GT, Buckton S, Connell W, Pavli P, Raven L, Andrews JM.

Intern Med J. 2019 Nov 9. doi: 10.1111/imj.14683. [Epub ahead of print]

PMID:
31707751
2.

Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis.

An YK, Prince D, Gardiner F, Neeman T, Linedale EC, Andrews JM, Connor S, Begun J.

Med J Aust. 2019 Nov;211(10):461-467. doi: 10.5694/mja2.50384. Epub 2019 Nov 3. Review.

PMID:
31680263
3.

RAG-Mediated DNA Breaks Attenuate PU.1 Activity in Early B Cells through Activation of a SPIC-BCLAF1 Complex.

Soodgupta D, White LS, Yang W, Johnston R, Andrews JM, Kohyama M, Murphy KM, Mosammaparast N, Payton JE, Bednarski JJ.

Cell Rep. 2019 Oct 22;29(4):829-843.e5. doi: 10.1016/j.celrep.2019.09.026.

4.

Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.

Andrews JM, Schmidt JA, Carson KR, Musiek AC, Mehta-Shah N, Payton JE.

EBioMedicine. 2019 Aug;46:170-183. doi: 10.1016/j.ebiom.2019.07.053. Epub 2019 Jul 26.

5.

Fecal Microbiota Transplantation for Ulcerative Colitis-Reply.

Costello SP, Conlon MA, Andrews JM.

JAMA. 2019 Jun 11;321(22):2240-2241. doi: 10.1001/jama.2019.3950. No abstract available.

PMID:
31184735
6.

Establishing Absolute Lymphocyte Count Thresholds for Further Review of Peripheral Blood Lymphocytosis to Judiciously Screen for Monoclonal B-Cell Populations in Older Adults.

Muscara MJ, Cook BA, Dhesi MS, Groo SC, Andrews JM.

Am J Clin Pathol. 2019 Sep 9;152(4):458-462. doi: 10.1093/ajcp/aqz057.

PMID:
31165137
7.

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.

Julsgaard M, Hvas CL, Gearry RB, Gibson PR, Fallingborg J, Sparrow MP, Bibby BM, Connell WR, Brown SJ, Kamm MA, Lawrance IC, Vestergaard T, Svenningsen L, Baekdal M, Kammerlander H, Walsh A, Boysen T, Bampton P, Radford-Smith G, Kjeldsen J, Andrews JM, Subramaniam K, Moore GT, Jensen NM, Connor SJ, Wildt S, Wilson B, Ellard K, Christensen LA, Bell SJ.

Inflamm Bowel Dis. 2020 Jan 1;26(1):93-102. doi: 10.1093/ibd/izz110.

PMID:
31141607
8.

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.

Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM.

Cochrane Database Syst Rev. 2019 Apr 12;4:CD012680. doi: 10.1002/14651858.CD012680.pub2.

PMID:
30977111
9.

Systematic review of rectal stump management during and after emergency total colectomy for acute severe ulcerative colitis.

Bedrikovetski S, Dudi-Venkata N, Kroon HM, Liu J, Andrews JM, Lewis M, Lawrence M, Sammour T.

ANZ J Surg. 2019 Dec;89(12):1556-1560. doi: 10.1111/ans.15075. Epub 2019 Mar 28. Review.

PMID:
30919553
10.

Integrated Psychological Care is Needed, Welcomed and Effective in Ambulatory Inflammatory Bowel Disease Management: Evaluation of a New Initiative.

Lores T, Goess C, Mikocka-Walus A, Collins KL, Burke ALJ, Chur-Hansen A, Delfabbro P, Andrews JM.

J Crohns Colitis. 2019 Jul 25;13(7):819-827. doi: 10.1093/ecco-jcc/jjz026.

PMID:
30721977
11.

Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial.

Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C, Rosewarne CP, Bickley C, Peters C, Schoeman MN, Conlon MA, Roberts-Thomson IC, Andrews JM.

JAMA. 2019 Jan 15;321(2):156-164. doi: 10.1001/jama.2018.20046.

12.

Crohn's & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia.

Massuger W, Moore GTC, Andrews JM, Kilkenny MF, Reyneke M, Knowles S, Purcell L, Alex G, Buckton S, Page AT, Stocks N, Cameron D, Manglaviti F, Pavli P.

Intern Med J. 2019 Jul;49(7):859-866. doi: 10.1111/imj.14187.

PMID:
30525299
13.

Letter: vedolizumab drug concentrations in neonates following intrauterine exposure.

Flanagan E, Gibson PR, Begun J, Ghaly S, Garg M, Andrews JM, Rosella O, Rosella G, Bell SJ.

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1328-1330. doi: 10.1111/apt.15027. No abstract available.

PMID:
30488628
14.

Referrals to a tertiary hospital: A window into clinical management issues in functional gastrointestinal disorders.

Linedale EC, Shahzad MA, Kellie AR, Mikocka-Walus A, Gibson PR, Andrews JM.

JGH Open. 2017 Oct 31;1(3):84-91. doi: 10.1002/jgh3.12015. eCollection 2017 Nov.

15.

Authors' reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin and Quality of Life.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM.

Inflamm Bowel Dis. 2019 May 4;25(6):e62-e63. doi: 10.1093/ibd/izy338. No abstract available.

PMID:
30380064
16.

Diabetic Bladder Dysfunction:A Review.

Wittig L, Carlson KV, Andrews JM, Crump RT, Baverstock RJ.

Urology. 2019 Jan;123:1-6. doi: 10.1016/j.urology.2018.10.010. Epub 2018 Oct 21. Review.

PMID:
30352207
17.

Epigenetic dynamics in normal and malignant B cells: die a hero or live to become a villain.

Andrews JM, Payton JE.

Curr Opin Immunol. 2019 Apr;57:15-22. doi: 10.1016/j.coi.2018.09.020. Epub 2018 Oct 17. Review.

PMID:
30342313
18.

Investigating the effect of early bladder management in patients with chronic kidney disease and diabetes: Lessons learned from a failed pilot study.

Wittig L, Andrews JM, Crump RT, Carlson KV, Baverstock RJ.

Can Urol Assoc J. 2018 Oct;12(10):301-302. doi: 10.5489/cuaj.5304. Epub 2018 May 28. No abstract available.

19.

Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM.

Inflamm Bowel Dis. 2019 Feb 21;25(3):592-600. doi: 10.1093/ibd/izy278.

PMID:
30215805
20.

Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman SN, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM.

Nutrients. 2018 Sep 1;10(9). pii: E1192. doi: 10.3390/nu10091192.

21.

Investigating the effect of early bladder management in patients with chronic kidney disease and diabetes: Lessons learned from a failed pilot study.

Wittig LA, Andrews JM, Crump RT, Carlson KV, Baverstock RJ.

Can Urol Assoc J. 2018 May 28. doi: 10.5489/cuaj.5034. [Epub ahead of print] No abstract available.

PMID:
29989914
22.

Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease.

Roberts RL, Wallace MC, Seinen ML, van Bodegraven AA, Krishnaprasad K, Jones GT, van Rij AM, Baird A, Lawrance IC, Prosser R, Bampton P, Grafton R, Simms LA, Studd C, Bell SJ, Kennedy MA, Halliwell J, Gearry RB, Radford-Smith G, Andrews JM, McHugh PC, Barclay ML.

Inflamm Bowel Dis. 2018 Nov 29;24(12):2606-2612. doi: 10.1093/ibd/izy163.

PMID:
29788244
23.

Multidisciplinary team meetings appear to be effective in inflammatory bowel disease management: an audit of process and outcomes.

Ferman M, Lim AH, Hossain M, Siow GW, Andrews JM.

Intern Med J. 2018 Sep;48(9):1102-1108. doi: 10.1111/imj.13965.

PMID:
29761611
24.

It is high time to examine the psyche while treating IBD.

Mikocka-Walus A, Andrews JM.

Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):329-330. doi: 10.1038/s41575-018-0004-y. No abstract available.

PMID:
29636536
25.

Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.

Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR.

J Crohns Colitis. 2018 May 25;12(6):653-661. doi: 10.1093/ecco-jcc/jjy003.

PMID:
29385469
26.

Predictors of Impaired Mental Health and Support Seeking in Adults With Inflammatory Bowel Disease: An Online Survey.

Knowles S, Andrews JM, Porter A.

Gastroenterol Nurs. 2018 Jan/Feb;41(1):38-46. doi: 10.1097/SGA.0000000000000251.

PMID:
29373354
27.

Genotify: Fast, lightweight gene lookup and summarization.

Andrews JM, El-Alawi M, Payton JE.

J Open Source Softw. 2018;3(28). pii: 885. doi: 10.21105/joss.00885. Epub 2018 Aug 15. No abstract available.

28.

Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.

Daveson AJM, Ee HC, Andrews JM, King T, Goldstein KE, Dzuris JL, MacDougall JA, Williams LJ, Treohan A, Cooreman MP, Anderson RP.

EBioMedicine. 2017 Dec;26:78-90. doi: 10.1016/j.ebiom.2017.11.018. Epub 2017 Nov 22.

29.

Performance of an algorithm-based approach to the diagnosis and management of functional gastrointestinal disorders: A pilot trial.

Linedale EC, Mikocka-Walus A, Vincent AD, Gibson PR, Andrews JM.

Neurogastroenterol Motil. 2018 Jan;30(1). doi: 10.1111/nmo.13243. Epub 2017 Nov 2.

PMID:
29094806
30.

Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.

Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1037-1053. doi: 10.1111/apt.14368. Epub 2017 Oct 13. Review.

31.

Diagnosis and management of irritable bowel syndrome: a guide for the generalist.

Linedale EC, Andrews JM.

Med J Aust. 2017 Sep 2;207(7):309-315. Review.

PMID:
28954618
32.

Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method.

Chen GB, Lee SH, Montgomery GW, Wray NR, Visscher PM, Gearry RB, Lawrance IC, Andrews JM, Bampton P, Mahy G, Bell S, Walsh A, Connor S, Sparrow M, Bowdler LM, Simms LA, Krishnaprasad K; International IBD Genetics Consortium, Radford-Smith GL, Moser G.

BMC Med Genet. 2017 Aug 29;18(1):94. doi: 10.1186/s12881-017-0451-2.

33.

Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice.

Bryant RV, Costello SP, Schoeman S, Sathananthan D, Knight E, Lau SY, Schoeman MN, Mountifield R, Tee D, Travis SPL, Andrews JM.

J Gastroenterol Hepatol. 2018 Mar;33(3):599-607. doi: 10.1111/jgh.13923.

PMID:
28806471
34.

Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet? Authors' reply.

Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM.

Aliment Pharmacol Ther. 2017 Sep;46(6):631-632. doi: 10.1111/apt.14246. No abstract available.

35.

Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities?

Andrews JM.

Aliment Pharmacol Ther. 2017 Jul;46(2):201-202. doi: 10.1111/apt.14115. No abstract available.

36.

Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis.

Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM.

Aliment Pharmacol Ther. 2017 Aug;46(3):213-224. doi: 10.1111/apt.14173. Epub 2017 Jun 14. Review.

37.

Longitudinal analysis indicates symptom severity influences immune profile in irritable bowel syndrome.

Mavrangelos C, Campaniello MA, Andrews JM, Bampton PA, Hughes PA.

Gut. 2018 Feb;67(2):398-399. doi: 10.1136/gutjnl-2017-314308. Epub 2017 Jun 10. No abstract available.

PMID:
28601848
38.

Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice.

Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, Karmiris K, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN.

World J Gastroenterol. 2017 Apr 28;23(16):2995-3002. doi: 10.3748/wjg.v23.i16.2995.

39.

The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus.

Bye WA, Sparrow MP, Connor SJ, Andrews JM, Ellard K, Ng W, Hume G, Antoniades S, Walsh AJ.

Intern Med J. 2017 Nov;47(11):1263-1269. doi: 10.1111/imj.13488.

PMID:
28516725
40.

Inpatient iron deficiency detection and management: how do general physicians and gastroenterologists perform in a tertiary care hospital?

Fazal MW, Andrews JM, Thomas J, Saffouri E.

Intern Med J. 2017 Aug;47(8):928-932. doi: 10.1111/imj.13486.

PMID:
28509435
41.

Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.

Goel G, King T, Daveson AJ, Andrews JM, Krishnarajah J, Krause R, Brown GJE, Fogel R, Barish CF, Epstein R, Kinney TP, Miner PB Jr, Tye-Din JA, Girardin A, Taavela J, Popp A, Sidney J, Mäki M, Goldstein KE, Griffin PH, Wang S, Dzuris JL, Williams LJ, Sette A, Xavier RJ, Sollid LM, Jabri B, Anderson RP.

Lancet Gastroenterol Hepatol. 2017 Jul;2(7):479-493. doi: 10.1016/S2468-1253(17)30110-3. Epub 2017 May 11.

42.

A type I IFN-dependent DNA damage response regulates the genetic program and inflammasome activation in macrophages.

Morales AJ, Carrero JA, Hung PJ, Tubbs AT, Andrews JM, Edelson BT, Calderon B, Innes CL, Paules RS, Payton JE, Sleckman BP.

Elife. 2017 Mar 31;6. pii: e24655. doi: 10.7554/eLife.24655.

43.

Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis.

Lawrance IC, Baird A, Lightower D, Radford-Smith G, Andrews JM, Connor S.

Clin Gastroenterol Hepatol. 2017 Aug;15(8):1248-1255. doi: 10.1016/j.cgh.2017.02.027. Epub 2017 Mar 7.

PMID:
28286194
44.

Is There a Link Between H. Pylori and the Epidemiology of Crohn's Disease?

Shah A, Talley NJ, Walker M, Koloski N, Morrison M, Burger D, Andrews JM, McGuckin M, Jones M, Holtmann G.

Dig Dis Sci. 2017 Sep;62(9):2472-2480. doi: 10.1007/s10620-017-4496-z. Epub 2017 Mar 9. Review.

PMID:
28281167
45.

Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.

Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, Lewindon P, Jones LV, Sewell K, Krishnaprasad K, Prosser R, Marr D, Fischer J, R Thomas G, Tehan JV, Ding NS, Cooke SE, Moss K, Sechi A, De Cruz P, Grafton R, Connor SJ, Lawrance IC, Gearry RB, Andrews JM, Radford-Smith GL; Australian and New Zealand Inflammatory Bowel Disease Consortium.

Aliment Pharmacol Ther. 2017 Feb;45(4):542-552. doi: 10.1111/apt.13880. Epub 2016 Dec 19.

46.

Serologic antibodies in relation to outcome in postoperative Crohn's disease.

Hamilton AL, Kamm MA, De Cruz P, Wright EK, Selvaraj F, Princen F, Gorelik A, Liew D, Lawrance IC, Andrews JM, Bampton PA, Sparrow MP, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Bell SJ, Brown SJ, Connell WR.

J Gastroenterol Hepatol. 2017 Jun;32(6):1195-1203. doi: 10.1111/jgh.13677.

PMID:
27976801
47.

Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial.

Mikocka-Walus A, Hughes PA, Bampton P, Gordon A, Campaniello MA, Mavrangelos C, Stewart BJ, Esterman A, Andrews JM.

J Crohns Colitis. 2017 Apr 1;11(4):509-514. doi: 10.1093/ecco-jcc/jjw165.

48.

Magnetic-adhesive based valves for microfluidic devices used in low-resource settings.

Harper JC, Andrews JM, Ben C, Hunt AC, Murton JK, Carson BD, Bachand GD, Lovchik JA, Arndt WD, Finley MR, Edwards TL.

Lab Chip. 2016 Oct 18;16(21):4142-4151.

PMID:
27713988
49.

Inpatient healthcare utilisation in patients with alcoholic liver disease: what are the costs and outcomes?

Williamson KD, Gill MG, Andrews JM, Harley HA.

Intern Med J. 2016 Dec;46(12):1407-1413. doi: 10.1111/imj.13258. Erratum in: Intern Med J. 2017 Apr;47(4):475.

PMID:
27643595
50.

Patient satisfaction with treatment for alcohol use disorders: comparing patients with and without severe mental health symptoms.

McCallum SL, Andrews JM, Gaughwin MD, Turnbull DA, Mikocka-Walus AA.

Patient Prefer Adherence. 2016 Aug 4;10:1489-500. doi: 10.2147/PPA.S92902. eCollection 2016.

Supplemental Content

Loading ...
Support Center